Sam-A Pharm삼아제약

Sam-A Pharm's profits have fallen sharply from their 2023-2024 peak, though the share price is up over three months and remains below its 52-week high.

Sam-A Pharm is a Seoul-based Korean drugmaker that sells prescription medicines, general medicines and health functional foods, with its main plant in Wonju. Trailing revenue to H1 2026 is about ₩72.3B, down from ₩95.6B in 2024, and operating margin has eased to 7.6%. The shares closed at ₩13,700 on 27 October 2026, about 20% below the 52-week high of ₩17,130 but above the low of ₩11,950.

What stands out

• Revenue fell 18.6% in 2025 to ₩77.8B after peaking near ₩97B in 2023, and operating income dropped from ₩24.5B in 2024 to ₩11.0B in 2025.
• Trailing net income of ₩10.5B is well above trailing operating income of ₩5.5B, which suggests non-operating items helped profit; the data does not explain the source.
• Valuation metrics are low: P/E about 8.3, P/B about 0.4, and enterprise value about ₩10.7B against cash of ₩19.6B and borrowings of ₩2.7B.
• ROE is 4.7% on a trailing basis, and the company pays no dividend according to the data.
• Foreign ownership is small at 2.8%, and 20-day flows were net negative from foreign investors while retail investors were net buyers.

What to watch

• The next quarterly report for Sep 2026 and whether revenue and operating margin stabilise after the 2025 decline.
• Whether the corporate value-up plan filed in March 2026 leads to concrete follow-up filings, since the data gives no details.
• The data contains no recent news headlines, so any new company announcements would need to be checked in the filings.